🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Moderate-to-severe Inflammatory Bowel Disease

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease NCT06958536Phase 266 sites📍 Tucson📍 Escondido📍 Lancaster Sanofi · Tests: brivekimig, Placebo A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease NCT05837897Phase 341 sites📍 Hefei📍 Wuhu📍 Beijing Takeda · Tests: Vedolizumab IV, Placebo A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) NCT04779320Phase 396 sites📍 Phoenix📍 Los Angeles📍 San Diego Takeda · Tests: Vedolizumab IV Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis NCT07686081Phase 32 sites📍 Chula Vista📍 Nashville Vanda Pharmaceuticals · Tests: Ponesimod, Placebo An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis NCT07184996Phase 3240 sites📍 Peoria📍 Scottsdale📍 Scottsdale Sanofi · Tests: Duvakitug, Placebo An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease NCT07184931Phase 3461 sites📍 Peoria📍 Scottsdale📍 Scottsdale Sanofi · Tests: Duvakitug, Placebo A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease NCT05995353Phase 385 sites📍 Phoenix📍 Little Rock📍 Oakland AbbVie · Tests: Risankizumab, Risankizumab A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease NCT07483073Phase 270 sites📍 Scottsdale📍 Los Angeles📍 Oxnard Eli Lilly and Company · Tests: Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC), LY4395089 A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) NCT06764615Phase 216 sites📍 Glen Burnie📍 Tyler📍 Chongqing Takeda · Tests: Zasocitinib Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease NCT07078994Phase 220 sites📍 Barnaul📍 Ufa📍 Moscow Biocad · Tests: anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, hig… Hyperbaric Oxygen Therapy for Ulcerative Colitis (HBOT-UC) NCT05987852NA13 sites📍 Birmingham📍 Los Angeles📍 Miami Northwestern University · Tests: Hyperbaric Oxygen Therapy, Sham Hyperbaric Air A Study to Evaluate the Safety of SHR-7590 in Chinese Healthy Participants and in Patients With Moderate-to-severe Inflammatory Bowel Disease NCT07758101Phase 11 site📍 Hangzhou Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-7590, Placebo A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease NCT07499232Phase 3161 sites📍 Dothan📍 Mobile📍 Anaheim Janssen Research & Development, LLC · Tests: Guselkumab, Risankizumab Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis NCT07080034Phase 220 sites📍 Barnaul📍 Ufa📍 Rostov-on-Don Biocad · Tests: anti-TL1A monoclonal antibody, low dose, anti-TL1A monoclonal antibody, medium dose, anti-TL1A monoclonal antibody, hig… A Study for HSK47388 in Participants With Ulcerative Colitis NCT07335055Phase 21 site📍 Hangzhou Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK47388, Placebo A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis NCT07071519Phase 372 sites📍 Phoenix📍 San Diego📍 San Francisco AbbVie · Tests: Risankizumab, Risankizumab Treatment of Moderate to Severe Refractory Crohn's Disease NCT06721962Phase 1, Phase 213 sites📍 Scottsdale📍 Sacramento📍 San Francisco Tr1X, Inc. · Tests: TRX103, Cyclophosphamide Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study NCT06937086Phase 3187 sites📍 Dothan📍 Anaheim📍 Beverly Hills Eli Lilly and Company · Tests: Mirikizumab, Mirikizumab, Tirzepatide, Placebo A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease NCT06226883Phase 2225 sites📍 Lancaster📍 San Diego📍 Colorado Springs Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli… · Tests: Placebo, MORF-057 Efficacy and Safety of Guselkumab in Patients With Moderate-to-Severe Ulcerative Colitis NCT07726888n/a1 site📍 Wenzhou Second Affiliated Hospital of Wenzhou Medical University · Tests: Guselkumab LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis: NCT07186101Phase 2147 sites📍 Scottsdale📍 Anaheim📍 Lancaster Eli Lilly and Company · Tests: LY4268989, Mirikizumab, LY4268989 Placebo A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease NCT07483099Phase 270 sites📍 Scottsdale📍 Los Angeles📍 Oxnard Eli Lilly and Company · Tests: LY4395089, Mirikizumab - Intravenous (IV), Mirikizumab - Subcutaneous (SC) A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis NCT06865417Phase 346 sites📍 Brussels📍 Liège📍 Namur Alfasigma S.p.A. · Tests: Filgotinib Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease NCT06456593Phase 2149 sites📍 Fairhope📍 Scottsdale📍 Sun City Abivax S.A. · Tests: Obefazimod, Placebo Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis NCT06453317Phase 21 site📍 Lodz Medical University of Lodz · Tests: Infliximab, Ustekinumab A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis NCT07012395Phase 2273 sites📍 Canoga Park📍 La Jolla📍 Lancaster Spyre Therapeutics, Inc. · Tests: SPY001, SPY002, SPY003, Placebo A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease NCT07196722Phase 2, Phase 3372 sites📍 Chandler📍 Litchfield Park📍 Scottsdale Janssen Research & Development, LLC · Tests: Icotrokinra, Placebo A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease NCT06233461Phase 2201 sites📍 Murrieta📍 Orange📍 Clearwater Takeda · Tests: TAK-279, Placebo The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC NCT07507513Phase 21 site📍 Guangzhou Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Tests: 627, Placebo Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis NCT06619990Phase 1, Phase 298 sites📍 Scottsdale📍 Palo Alto📍 Bradenton Xencor, Inc. · Tests: XmAb942, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy